ICON plc Q1 2025 Results Period Ended March 31, 2025 Forward Looking Statement Statements included in this presentation which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Forward-looking statements include statements regarding our financial guidance and outlook, and may be identified by the use of future tense or other forward-looking words s ...

Core Viewpoint - ICON PLC is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and undisclosed material losses impacting its business operations [1][3]. Company Overview - ICON PLC is identified as a clinical research organization (CRO) [2][3]. Allegations in the Lawsuit - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations affecting its client base [3]. - It is alleged that ICON's Functional Service Provision (FSP) and hybrid model offerings were inadequate to mitigate the effects of a significant market downturn [3]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than indicative of actual client demand [3]. - Customers of ICON are said to have canceled contracts, limited engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [3]. - The two largest customers of ICON were diversifying their CRO providers away from ICON [3]. - As a result of these issues, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [3]. - Consequently, ICON was tracking significantly below the 2024 revenue and EPS guidance issued during the Class Period, which lacked a reasonable factual basis [3]. Financial Performance - On October 23, 2024, ICON reported quarterly revenues of $2.03 billion, missing consensus estimates of $2.13 billion by over $100 million [4]. - The quarterly net new business wins declined to $2.3 billion from $2.6 billion in the prior quarter, and the book-to-bill ratio fell to 1.15 from 1.22 [4]. - The CEO indicated that two large pharmaceutical customers had curtailed upcoming FSP trial work due to ongoing cost containment measures, which would negatively impact financial performance [4]. - Following this news, the price of ICON ordinary shares dropped by more than 20% over two trading sessions [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ICON Public Limited Company regarding a class action lawsuit due to alleged misleading statements and undisclosed material losses during a specified class period [1]. Allegations Summary - ICON experienced a significant loss of business attributed to customer cost reduction measures and funding limitations affecting its client base [1]. - The company's service provision and hybrid model offerings were inadequate to mitigate the impacts of a market downturn [1]. - Requests for proposals from biotechnology customers were primarily used for price discovery rather than reflecting actual client demand [1]. - Customers canceled contracts, reduced engagements, and delayed clinical trial work, leading to a decline in new contracts at historical rates [1]. - ICON's two largest customers began diversifying their clinical research organization providers away from the company [1]. - The reported net new business awards and book-to-bill metrics misrepresented actual client demand for ICON's services [1]. - As a result of the above factors, ICON's performance was significantly below the 2024 revenue and EPS guidance provided during the class period, which lacked a reasonable factual basis [1]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 11, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ICON Public Limited Company regarding a class action lawsuit due to alleged misleading statements and failure to disclose material information during the class period from July 27, 2023, to October 23, 2024 [1]. Allegations Summary - ICON is accused of suffering a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [1]. - The company's functional service provision and hybrid model offerings were deemed insufficient to protect against a significant market downturn [1]. - Requests for proposals from biotechnology customers were primarily used for price discovery, not indicative of actual client demand [1]. - Customers canceled contracts, limited engagements, delayed clinical trial work, and failed to enter new contracts at historical rates [1]. - ICON's two largest customers were diversifying their clinical research organization providers away from the company [1]. - As a result of the above issues, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [1]. - Consequently, ICON was tracking significantly below the 2024 revenue and EPS guidance issued during the class period, which lacked a reasonable factual basis [1]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 11, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Insights - Parexel, a leading clinical research organization (CRO), appointed Jeff Bernstein to its Board of Directors effective March 5, 2025, succeeding Michael Bruun as part of a planned rotation [1][5] - Bernstein's extensive experience in healthcare investment and public company board service is expected to enhance Parexel's strategic roadmap and growth objectives [2][3] Company Overview - Parexel is among the largest CROs globally, providing comprehensive Phase I to IV clinical development services aimed at expediting life-saving treatments to patients [4] - The company employs over 21,000 professionals and collaborates with biopharmaceutical leaders and emerging innovators to design and deliver clinical trials [4] - Parexel has received multiple industry recognitions, including the 2024 and 2023 SCRS Eagle Award and being named "Best Contract Research Organization" in November 2023 [4] Leadership Transition - Michael Bruun, who served on the board for two years, is recognized for his contributions, and the company expresses gratitude for his leadership [2] - Jeff Bernstein's background includes serving on various healthcare boards and a strong educational foundation in Economics and Finance from Princeton University [3] Strategic Focus - The appointment of Bernstein aligns with Parexel's commitment to leveraging unique insights and driving best-in-class delivery to achieve market-leading growth in 2025 [2][5] - The company aims to innovate and differentiate itself in the CRO space, enhancing its position and accelerating the delivery of new therapies to patients globally [4]

Core Viewpoint - A lawsuit has been filed against ICON plc and its senior executives for potential violations of federal securities laws, stemming from claims of misleading representations regarding client demand and business performance [1][2][3]. Company Overview - ICON plc is a clinical research organization (CRO) that assists pharmaceutical companies in bringing new drugs to market [3]. - The company has faced challenges as large pharmaceutical firms have implemented cost reduction measures, including shifting clinical studies in-house, which has negatively impacted ICON's business [3][4]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Eastern District of New York, titled Shing v. ICON plc, et al., No. 25-cv-00763 [2]. - Investors have until April 11, 2025, to request to be appointed to lead the case [2]. Financial Performance and Stock Impact - On October 23, 2024, ICON reported a quarterly revenue shortfall exceeding $100 million, leading to a significant decline in stock price by over 20% within two days [5]. - The company also cut its annual revenue guidance for 2024 by $220 million due to deteriorating customer demand and project cancellations [5]. - On January 14, 2025, ICON issued financial guidance for 2025 that fell below analysts' expectations, resulting in an 8% drop in stock price [6].